Rajwanth Veluswamy, Associate Professor of Medicine at NYU Langone Health, shared a post on LinkedIn:
“Excited to share the launch of the KRAS Excellence Initiative at NYU Langone’s Perlmutter Cancer Center – a multidisciplinary effort focused on advancing clinical trials, translational research, and discoveries in KRAS biology to improve care for patients with KRAS-mutated cancers.
KRAS has long been considered one of the most challenging targets in oncology, but the field is evolving rapidly. Through this initiative, we are bringing together deep scientific expertise, innovative clinical trials, and cross-disciplinary collaboration to help patients access novel therapies and strategies across cancer types.
I am proud to be part of this effort alongside Paul Oberstein, Anirban Maitra, John Leonard, and many colleagues across NYU Langone and Perlmutter Cancer Center committed to advancing care for patients with KRAS-driven cancers.”
Learn more here: KRAS Excellence Initiative
Other articles on OncoDaily.